相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Kimberley M. Heinhuis et al.
JAMA ONCOLOGY (2020)
The therapeutic potential of targeting tryptophan catabolism in cancer
Christiane A. Opitz et al.
BRITISH JOURNAL OF CANCER (2020)
Immune related adverse events and response to immunotherapy: Focus on corticosteroids
Alice Indini et al.
LUNG CANCER (2020)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
Alexander M. M. Eggermont et al.
JAMA ONCOLOGY (2020)
Different effects of tryptophan 2,3-dioxygenase inhibition on SK-Mel-28 and HCT-8 cancer cell lines
Sara Paccosi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Rational design of anti-GITR-based combination immunotherapy
Roberta Zappasodi et al.
NATURE MEDICINE (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Current state on tryptophan 2,3-dioxygenase inhibitors: a patent review
Arina Kozlova et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal
Mixue Xie et al.
CELL DEATH & DISEASE (2019)
The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease
Veit Rothhammer et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Involvement of upregulation of fibronectin in the pro-adhesive and pro-survival effects of glucocorticoid on melanoma cells
Gao-Xiang Huang et al.
MOLECULAR MEDICINE REPORTS (2018)
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab
Susan C. Scott et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness
Stefania Rossi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Lieve Brochez et al.
EUROPEAN JOURNAL OF CANCER (2017)
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
Yuying Liu et al.
NATURE COMMUNICATIONS (2017)
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
Marc Hennequart et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Up-regulation of Rho-associated kinase 1/2 by glucocorticoids promotes migration, invasion and metastasis of melanoma
Gao-xiang Huang et al.
CANCER LETTERS (2017)
Immunotherapy in melanoma: Recent advances and future directions
C. Franklin et al.
EJSO (2017)
Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies
Alistair M. Cook et al.
ONCOIMMUNOLOGY (2016)
New dimension of glucocorticoids in cancer treatment
Kai-Ti Lin et al.
STEROIDS (2016)
Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis
Ya-Ling Hsu et al.
ONCOTARGET (2016)
Development and characterization of an in vitro model of colorectal adenocarcinoma with MDR phenotype
Lorenzo Cinci et al.
CANCER MEDICINE (2016)
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells
Olga Novikov et al.
MOLECULAR PHARMACOLOGY (2016)
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma
Erica M. Stringer-Reasor et al.
GYNECOLOGIC ONCOLOGY (2015)
Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase
Georgios Pantouris et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells
Takashi Sumikawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6-and glutathione-dependent mechanism
Soraya L. Valles et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Dexamethasone accelerates degradation of aryl hydrocarbon receptor (AHR) and suppresses CYP1A1 induction in placental JEG-3 cell line
Lucie Stejskalova et al.
TOXICOLOGY LETTERS (2013)
The monocyte chemotactic protein synthesis inhibitor bindarit prevents mesangial cell proliferation and extracellular matrix remodeling
Sara Paccosi et al.
PHARMACOLOGICAL RESEARCH (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
Glucocorticoid Receptor Expression and Antiproliferative Effect of Dexamethasone on Human Melanoma Cells
Judit Dobos et al.
PATHOLOGY & ONCOLOGY RESEARCH (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
The aryl hydrocarbon receptor (AHR), a novel regulator of human melanogenesis
Sandra Luecke et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy
Bruce D. Keith
BMC CANCER (2008)
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy
Ursula Grohmann et al.
NATURE MEDICINE (2007)
Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors
Chengwen Zhang et al.
CANCER BIOLOGY & THERAPY (2007)
Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients
Georg Weinlich et al.
DERMATOLOGY (2007)
Quantitative and spatial differences in the expression of tryptophan-metabolizing enzymes in mouse epididymis
A Britan et al.
CELL AND TISSUE RESEARCH (2006)
Role of phosphatidylinositol-3 kinase in regulation of differential sensitivity of melanoma cells to antitumor agents. A model for hormone resistance development in tumor cells
MA Krasil'nikov et al.
BIOCHEMISTRY-MOSCOW (2004)
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells
M Tone et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Nontranscriptional actions of the glucocorticoid receptor
FP Limbourg et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2003)
Overexpression of the aryl hydrocarbon receptor (AhR) accelerates the cell proliferation of A549 cells
S Shimba et al.
JOURNAL OF BIOCHEMISTRY (2002)
Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance
J Shimizu et al.
NATURE IMMUNOLOGY (2002)
分享论文
